Memphasys Ltd (AU:MEM) has released an update.
Memphasys Ltd has announced a capital raising effort of A$2.0 million to accelerate the commercialization of its Felix™ System and strategic partner discussions. The funds will support the finalization of a clinical trial in Japan, a study to advance global commercial sales for equine fertility, and a study on oxidative stress related to reproductive performance. This capital boost is expected to pave the way for significant commercial and strategic partnership opportunities.
For further insights into AU:MEM stock, check out TipRanks’ Stock Analysis page.
